GlassScriptPhysician profile
Matthew N Magdic
NPI 1922461052
$5,113.21
in general payments reported to CMS, 2019-2025
16 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $460 · 2022: $529 · 2023: $1,745 · 2024: $2,245 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $865 · Consulting Fee: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $865.00 |
| Consulting Fee | $720.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,613.47 | 2021-2025 | Korsuva, Veltassa |
| Travere Therapeutics, INC. | $1,111.54 | 2023-2024 | |
| Horizon Therapeutics Plc | $1,001.43 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $272.23 | 2023-2024 | |
| Ardelyx, INC. | $257.17 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Astrazeneca Pharmaceuticals LP | $238.10 | 2021-2025 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $155.08 | 2023-2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $141.36 | 2021-2025 | |
| Akebia Therapeutics INC | $109.19 | 2021-2024 | Auryxia |
| Fresenius USA Marketing, INC. | $75.96 | 2023-2024 | Velphoro, Korsuva |
| Bard Peripheral Vascular, INC. | $45.04 | 2021 | |
| Lilly USA, LLC | $21.54 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $20.80 | 2024 | Jynarque |
| Amgen INC. | $18.96 | 2024 | Krystexxa |
| Opko Pharmaceuticals, LLC | $17.26 | 2023 | Rayaldee |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.08 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Magdic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.